Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 148 articles:
HTML format
Text format



Single Articles


    August 2018
  1. SHETH V, Labopin M, Canaani J, Volin L, et al
    Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone Marrow Transplant. 2018 Aug 7. pii: 10.1038/s41409-018-0288.
    PubMed     Text format     Abstract available


    July 2018
  2. HIRANO M, Jimbo K, Ogawa M, Ochi K, et al
    Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0202.
    PubMed     Text format    


    June 2018
  3. TANG S, Shen H, Qu C, Dai H, et al
    Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Bone Marrow Transplant. 2018 Jun 25. pii: 10.1038/s41409-018-0249.
    PubMed     Text format     Abstract available


  4. GABELLI M, Zecca M, Messina C, Carraro E, et al
    Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0259.
    PubMed     Text format     Abstract available


  5. HOCHBERG J, Zahler S, Geyer MB, Chen N, et al
    The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leuke
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0247.
    PubMed     Text format     Abstract available


  6. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0248.
    PubMed     Text format    


  7. BONDA A, Punatar S, Gokarn A, Mohite A, et al
    Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
    Bone Marrow Transplant. 2018 Jun 8. pii: 10.1038/s41409-018-0222.
    PubMed     Text format    


    May 2018
  8. CRADDOCK C, Hoelzer D, Komanduri KV
    Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 May 31. pii: 10.1038/s41409-018-0203.
    PubMed     Text format     Abstract available


  9. KATO M, Kurata M, Kanda J, Kato K, et al
    Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0221.
    PubMed     Text format     Abstract available


  10. DREGER P, Michallet M, Bosman P, Dietrich S, et al
    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant. 2018 May 4. pii: 10.1038/s41409-018-0207.
    PubMed     Text format     Abstract available


    April 2018
  11. HALABURDA K, Labopin M, Houhou M, Niederwieser D, et al
    AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Bone Marrow Transplant. 2018 Apr 18. pii: 10.1038/s41409-018-0165.
    PubMed     Text format     Abstract available


  12. BATTIPAGLIA G, Ruggeri A, Labopin M, Volin L, et al
    Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Apr 16. pii: 10.1038/s41409-018-0169.
    PubMed     Text format     Abstract available


    March 2018
  13. BHATT VR, Chen B, Gyawali B, Lee SJ, et al
    Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Mar 27. pii: 10.1038/s41409-018-0164.
    PubMed     Text format     Abstract available


  14. GAAFAR A, Sheereen A, Almohareb F, Eldali A, et al
    Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
    Bone Marrow Transplant. 2018 Mar 16. pii: 10.1038/s41409-018-0123.
    PubMed     Text format     Abstract available


  15. MARKEY KA, Gartlan KH, Kuns RD, Lane SW, et al
    Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT.
    Bone Marrow Transplant. 2018 Mar 13. pii: 10.1038/s41409-018-0148.
    PubMed     Text format    


  16. INOUE Y, Fuji S, Tanosaki R, Inamoto Y, et al
    Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Bone Marrow Transplant. 2018 Mar 9. pii: 10.1038/s41409-018-0139.
    PubMed     Text format     Abstract available


  17. CHENG Z, Zhou L, Hu K, Dai Y, et al
    Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Mar 7. pii: 10.1038/s41409-018-0146.
    PubMed     Text format     Abstract available


    February 2018
  18. OCHI K, Fuji S, Takano K, Tajima K, et al
    The putative anti-leukemic effects of anti-thymocyte globulins in patients with CD7-positive acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Feb 19. pii: 10.1038/s41409-018-0115.
    PubMed     Text format     Abstract available


  19. BHATT VR, Chen B, Lee SJ
    Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study.
    Bone Marrow Transplant. 2018 Feb 5. pii: 10.1038/s41409-018-0105.
    PubMed     Text format     Abstract available


    January 2018
  20. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed     Text format    


  21. ALHASHIM N, Aljurf M, Hassanein M, Chaudhri N, et al
    Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-018-0093.
    PubMed     Text format     Abstract available


  22. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed     Text format    


  23. AMRO ELSHOURY, Wallace PK, Borowitz MJ, Kader A, et al
    BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 17. pii: 10.1038/s41409-017-0036.
    PubMed     Text format    


  24. CESARO S, Crocchiolo R, Tridello G, Knelange N, et al
    Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0016.
    PubMed     Text format     Abstract available


  25. OGAWA H, Ikegame K, Daimon T, Uchida N, et al
    Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0028.
    PubMed     Text format    


  26. JIANG Z, Jia J, Yue C, Pang Y, et al
    Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0049.
    PubMed     Text format     Abstract available


  27. DEVILLIER R, Labopin M, Chevallier P, Ledoux MP, et al
    Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Ma
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0043.
    PubMed     Text format     Abstract available


    December 2017
  28. MILONE G, Sacchi N, Gallina A, Leotta S, et al
    Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0026.
    PubMed     Text format     Abstract available


  29. GADALLA SM, Wang T, Loftus D, Friedman L, et al
    No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0029.
    PubMed     Text format     Abstract available


  30. KETTERL TG, Wu D, Fromm JR, Soma L, et al
    Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0037.
    PubMed     Text format    


  31. VAN GORKOM G, van Gelder M, Eikema DJ, Blok HJ, et al
    Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0023.
    PubMed     Text format     Abstract available


    October 2017
  32. CHO C, Hsu M, Barba P, Maloy MA, et al
    Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    September 2017
  33. SCHEID C, de Wreede L, van Biezen A, Koenecke C, et al
    Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2017 Sep 11. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  34. KORDELAS L, Buttkereit U, Lindemann M, Koldehoff M, et al
    alphabeta-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  35. MODI D, Deol A, Kim S, Ayash L, et al
    Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    August 2017
  36. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  37. LAHTEENMAKI K, Wacklin P, Taskinen M, Tuovinen E, et al
    Haematopoietic stem cell transplantation induces severe dysbiosis in intestinal microbiota of paediatric ALL patients.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    July 2017
  38. GEETHAKUMARI PR, Leiby B, Nair R, Alpdogan SO, et al
    Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Jul 31. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  39. FERGUSON P, Craddock C
    Allogeneic transplantation in primary refractory AML.
    Bone Marrow Transplant. 2017;52:950-951.
    PubMed     Text format    


    June 2017
  40. NGUYEN S, Achour A, Souchet L, Vigouroux S, et al
    Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Societe Francaise de Gref
    Bone Marrow Transplant. 2017 Jun 26. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  41. TERAKURA S, Kuwatsuka Y, Yamasaki S, Wake A, et al
    GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.
    Bone Marrow Transplant. 2017 Jun 12. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  42. ZHANG R, Shi W, Wang HF, You Y, et al
    Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  43. LITZOW MR, Fielding AK, Luger SM, Paietta E, et al
    The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  44. GROS FX, Cazaubiel T, Forcade E, Lechevalier N, et al
    Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  45. SALEM R, Massoud R, Haffar B, Mahfouz R, et al
    Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  46. VAN DE PEPPEL RJ, von dem Borne PA, le Cessie S, de Boer MGJ, et al
    A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.
    Bone Marrow Transplant. 2017;52:883-888.
    PubMed     Text format     Abstract available


    May 2017
  47. JETHAVA YS, Sica S, Savani B, Socola F, et al
    Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
    Bone Marrow Transplant. 2017 May 15. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    April 2017
  48. YU J, Hu Y, Pu C, Liang Z, et al
    Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  49. SIMONIN M, Dalissier A, Labopin M, Willasch A, et al
    More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Workin
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  50. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  51. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  52. BILL M, Jentzsch M, Grimm J, Schubert K, et al
    Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  53. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2017;52:656.
    PubMed     Text format    


  54. SCHETELIG J, de Wreede LC, van Gelder M, Andersen NS, et al
    Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:552-560.
    PubMed     Text format     Abstract available


  55. ANDERSSON BS, Thall PF, Valdez BC, Milton DR, et al
    Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
    Bone Marrow Transplant. 2017;52:580-587.
    PubMed     Text format     Abstract available


    March 2017
  56. TERAKURA S, Wake A, Inamoto Y, Murata M, et al
    Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
    Bone Marrow Transplant. 2017;52:423-430.
    PubMed     Text format     Abstract available


  57. VAN GELDER M, de Wreede LC, Bornhauser M, Niederwieser D, et al
    Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:372-380.
    PubMed     Text format     Abstract available


  58. ANTAR A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, et al
    Inhibition of FLT3 in AML: a focus on sorafenib.
    Bone Marrow Transplant. 2017;52:344-351.
    PubMed     Text format     Abstract available


    February 2017
  59. O'HARE P, Lucchini G, Cummins M, Veys P, et al
    Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience.
    Bone Marrow Transplant. 2017 Feb 20. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  60. BLUM V, Heini AD, Novak U, Taleghani BM, et al
    Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.
    Bone Marrow Transplant. 2017 Feb 13. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  61. YAMASHITA T, Ikegame K, Kojima H, Tanaka H, et al
    Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Feb 6. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  62. EDER S, Labopin M, Finke J, Bunjes D, et al
    Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
    Bone Marrow Transplant. 2017;52:238-244.
    PubMed     Text format     Abstract available


    January 2017
  63. YANADA M, Kurosawa S, Kobayashi T, Ozawa Y, et al
    Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  64. ROUX C, Tifratene K, Socie G, Galambrun C, et al
    Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the societe Francophone de greffe de moelle et de therapie cellulaire (SFGM-TC).
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  65. BATTIPAGLIA G, Labopin M, Candoni A, Fanin R, et al
    Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  66. CAI WZ, Cen JN, Chen J, Chen F, et al
    Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  67. FUJIWARA H, Fuji S, Wake A, Kato K, et al
    Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  68. TODISCO E, Ciceri F, Boschini C, Giglio F, et al
    Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  69. DULERY R, Nibourel O, Gauthier J, Elsermans V, et al
    Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  70. CARRE M, Thiebaut-Bertrand A, Larrat S, Leroy V, et al
    Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  71. KHOURI IF, Sui D, Jabbour EJ, Samuels BI, et al
    Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
    Bone Marrow Transplant. 2017;52:28-33.
    PubMed     Text format     Abstract available


  72. ZHENG CC, Zhu XY, Tang BL, Zhang XH, et al
    Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Bone Marrow Transplant. 2017;52:88-94.
    PubMed     Text format     Abstract available


    December 2016
  73. BUCCISANO F, Maurillo L, Piciocchi A, Del Principe MI, et al
    Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  74. ALLOIN AL, Leverger G, Dalle JH, Galambrun C, et al
    Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  75. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  76. TSIRIGOTIS P, Liga M, Gkirkas K, Stamouli M, et al
    Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  77. EL BOGHDADLY Z, Oran B, Jiang Y, Rondon G, et al
    Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  78. CHEN YB, Wang T, Hemmer MT, Brady C, et al
    GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  79. LEGRAND F, Le Floch AC, Granata A, Furst S, et al
    Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    November 2016
  80. ALBRING JC, Inselmann S, Sauer T, Schliemann C, et al
    PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    September 2016
  81. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  82. WILLASCH AM, Salzmann-Manrique E, Krenn T, Duerken M, et al
    Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  83. GATTI-MAYS ME, Manion M, Bowen LN, Brown GT, et al
    Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  84. BRAMMER JE, Saliba RM, Jorgensen JL, Ledesma C, et al
    Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  85. PHILLIPS EH, Hodson A, Hermine O, Bazarbachi A, et al
    Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  86. SIRVENT A, Auquier P, Oudin C, Bertrand Y, et al
    Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.
    Bone Marrow Transplant. 2016 Sep 5. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    August 2016
  87. O'DONNELL PV, Eapen M, Horowitz MM, Logan BR, et al
    Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.
    Bone Marrow Transplant. 2016 Aug 15. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  88. CHO WK, Ahn MB, Lee JW, Chung NG, et al
    Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?
    Bone Marrow Transplant. 2016 Aug 1. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    July 2016
  89. MAGENAU J, Westervelt P, Khaled S, McGuirk J, et al
    A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  90. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    June 2016
  91. TSIRIGOTIS P, Byrne M, Schmid C, Baron F, et al
    Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  92. POHLEN M, Groth C, Sauer T, Gorlich D, et al
    Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years).
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  93. SUN W, Gao F, Guo W, Wang B, et al
    Focused extracorporeal shock wave for osteonecrosis of the femoral head with leukemia after allo-HSCT: a case series.
    Bone Marrow Transplant. 2016 Jun 6. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    May 2016
  94. KRUGER P, Cooney J, Nivison-Smith I, Dodds A, et al
    All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.
    Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  95. LAM W, Viswabandya A, Hussain S, Messner HA, et al
    A unique case of tuberculosis dissemination presenting as cutaneous lesions in a post allogeneic stem cell transplant patient.
    Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  96. ADMIRAAL R, Chiesa R, Lindemans CA, Nierkens S, et al
    Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  97. RASHIDI A, DiPersio JF, Westervelt P, Abboud CN, et al
    HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  98. KOENECKE C, Heim D, van Biezen A, Heuser M, et al
    Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  99. HOCHBERG J, Harrison L, Morris E, Militano O, et al
    Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  100. RAMANATHAN M, Teira P, Battiwalla M, Barrett J, et al
    Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  101. PERL AE, Luger SM
    Allogeneic transplant for FLT3-ITD+ AML: room for improvement.
    Bone Marrow Transplant. 2016;51:508-10.
    PubMed     Text format    


  102. RUGGERI A, Labopin M, Ciceri F, Mohty M, et al
    Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.
    Bone Marrow Transplant. 2016;51:610-1.
    PubMed     Text format    


  103. DEFILIPP Z, Purcell M, Harris WA, Chandra DJ, et al
    Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.
    Bone Marrow Transplant. 2016;51:607-9.
    PubMed     Text format    


  104. MOGHNIEH R, Fawaz I, Mugharbil A, Jisr T, et al
    Clinical outcome and adverse events associated with empiric and pre-emptive use of amphotericin B lipid complex in a single center in lebanon.
    Bone Marrow Transplant. 2016;51:598-600.
    PubMed     Text format    


  105. SONG Y, Magenau J, Li Y, Braun T, et al
    FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
    Bone Marrow Transplant. 2016;51:511-20.
    PubMed     Text format     Abstract available


    March 2016
  106. BARON F, Beguin Y
    Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
    Bone Marrow Transplant. 2016 Mar 14. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  107. CHANG X, Zang X, Xia CQ
    New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
    Bone Marrow Transplant. 2016;51:324-32.
    PubMed     Text format     Abstract available


    February 2016
  108. ARITA K, Murakami J, Wada A, Miyazono T, et al
    Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus.
    Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  109. VAN GELDER M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, et al
    Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.
    Bone Marrow Transplant. 2016 Feb 15. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  110. CHRISTOPEIT M
    When is second allogeneic HSCT for relapse of acute leukaemia an option?
    Bone Marrow Transplant. 2016;51:184-5.
    PubMed     Text format    


  111. DEVILLIER R, Bramanti S, Furst S, Sarina B, et al
    T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
    Bone Marrow Transplant. 2016;51:194-8.
    PubMed     Text format     Abstract available


  112. VRHOVAC R, Labopin M, Ciceri F, Finke J, et al
    Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.
    Bone Marrow Transplant. 2016;51:186-93.
    PubMed     Text format     Abstract available


    January 2016
  113. MASCHAN M, Shelikhova L, Ilushina M, Kurnikova E, et al
    TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  114. BLEYZAC N, Cuzzubbo D, Renard C, Garnier N, et al
    Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  115. MIZUTANI M, Hara M, Fujita H, Aoki J, et al
    Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  116. LIANG CS, Quesada AE, Goswami M, Johnston PK, et al
    Phosphorylated STAT3 expression in hematopoietic stem cell transplant-associated large granular lymphocytic leukemia.
    Bone Marrow Transplant. 2016 Jan 11. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  117. NISHIWAKI S, Imai K, Mizuta S, Kanamori H, et al
    Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.
    Bone Marrow Transplant. 2016;51:43-50.
    PubMed     Text format     Abstract available


    December 2015
  118. AOKI J, Seo S, Kanamori H, Tanaka M, et al
    Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.
    Bone Marrow Transplant. 2015 Dec 7. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  119. XUE E, Tresoldi C, Sala E, Crippa A, et al
    Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse.
    Bone Marrow Transplant. 2015 Dec 7. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  120. GALE RP, Apperley JF
    Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.
    Bone Marrow Transplant. 2015;50:1582.
    PubMed     Text format    


    November 2015
  121. CAHU X, Labopin M, Giebel S, Aljurf M, et al
    Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.
    Bone Marrow Transplant. 2015 Nov 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    September 2015
  122. KROGER N, Bornhauser M, Stelljes M, Pichlmeier U, et al
    Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  123. CHANTEPIE SP, Michallet M, Blaise D, Maury S, et al
    Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy.
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format    


    July 2015
  124. HAHN M, Bottcher S, Dietrich S, Hegenbart U, et al
    Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
    Bone Marrow Transplant. 2015 Jul 6. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    June 2015
  125. WATANABE S, Waseda Y, Kimura H, Takato H, et al
    Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2015 Jun 8. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  126. YEW PY, Alachkar H, Yamaguchi R, Kiyotani K, et al
    Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2015 Jun 8. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  127. BONINI C, Peccatori J, Stanghellini MT, Vago L, et al
    Haploidentical HSCT: a 15-year experience at San Raffaele.
    Bone Marrow Transplant. 2015;50 Suppl 2:S67-71.
    PubMed     Text format     Abstract available


  128. MARTELLI MF, Ianni MD, Ruggeri L, Falzetti F, et al
    Next generation HLA-haploidentical HSCT.
    Bone Marrow Transplant. 2015;50 Suppl 2:S63-6.
    PubMed     Text format     Abstract available


  129. LANG P, Feuchtinger T, Teltschik HM, Schwinger W, et al
    Improved immune recovery after transplantation of TCRalphabeta/CD19-depleted allografts from haploidentical donors in pediatric patients.
    Bone Marrow Transplant. 2015;50 Suppl 2:S6-10.
    PubMed     Text format     Abstract available


  130. CHANG YJ, Huang XJ
    Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.
    Bone Marrow Transplant. 2015;50 Suppl 2:S21-3.
    PubMed     Text format     Abstract available


  131. AVERSA F
    T-cell depletion: from positive selection to negative depletion in adult patients.
    Bone Marrow Transplant. 2015;50 Suppl 2:S11-3.
    PubMed     Text format     Abstract available


  132. REISNER Y, Aversa F, Martelli MF
    Haploidentical hematopoietic stem cell transplantation: state of art.
    Bone Marrow Transplant. 2015;50 Suppl 2:S1-5.
    PubMed     Text format     Abstract available


  133. KAWANO H, Tanaka H, Yamashita T, Hirata KI, et al
    Very late-onset reversible cardiomyopathy in patients with chronic GvHD.
    Bone Marrow Transplant. 2015;50:870-2.
    PubMed     Text format    


  134. RESHEF R, Porter DL
    Reduced-intensity conditioned allogeneic SCT in adults with AML.
    Bone Marrow Transplant. 2015;50:759-69.
    PubMed     Text format     Abstract available


    May 2015
  135. STEINMANN J, Bertz H, Wasch R, Marks R, et al
    5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft.
    Bone Marrow Transplant. 2015;50:690-5.
    PubMed     Text format     Abstract available


  136. ALDOSS I, Dagis A, Palmer J, Forman S, et al
    Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.
    Bone Marrow Transplant. 2015;50:746-8.
    PubMed     Text format    


  137. GOSWAMI M, McGowan KS, Lu K, Jain N, et al
    A multigene array for measurable residual disease detection in AML patients undergoing SCT.
    Bone Marrow Transplant. 2015;50:642-51.
    PubMed     Text format     Abstract available


  138. VAXMAN I, Ram R, Gafter-Gvili A, Vidal L, et al
    Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.
    Bone Marrow Transplant. 2015;50:706-14.
    PubMed     Text format     Abstract available


    April 2015
  139. HOBBS GS, Hamdi A, Hilden PD, Goldberg JD, et al
    Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.
    Bone Marrow Transplant. 2015;50:493-8.
    PubMed     Text format     Abstract available


  140. WILK CM, Fischer JC, Schieren G, Rox JM, et al
    Treatment of donor-specific antibody-mediated graft rejection by immunochemotherapy, third-party DLI, plasmapheresis and immunoadsorption.
    Bone Marrow Transplant. 2015;50:613-4.
    PubMed     Text format    


  141. SAUER T, Silling G, Groth C, Rosenow F, et al
    Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.
    Bone Marrow Transplant. 2015;50:485-92.
    PubMed     Text format     Abstract available


  142. DE BRITO MD, Campilho F, Branca R, Vaz CP, et al
    Inadvertent transmission of occult CML through allo-SCT.
    Bone Marrow Transplant. 2015;50:598.
    PubMed     Text format    


    March 2015
  143. NIKOLAJEVA O, Mijovic A, Hess D, Tatam E, et al
    Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience.
    Bone Marrow Transplant. 2015 Mar 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  144. HARVEY J, Green A, Groves SJ, Cornish J, et al
    Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL.
    Bone Marrow Transplant. 2015;50:363-6.
    PubMed     Text format     Abstract available


  145. BEIER R, Maecker-Kolhoff B, Sykora KW, Chao M, et al
    Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML.
    Bone Marrow Transplant. 2015;50:463-4.
    PubMed     Text format    


  146. KIM M, Park J, Kim DW, Kim YJ, et al
    Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
    Bone Marrow Transplant. 2015;50:354-62.
    PubMed     Text format     Abstract available


  147. GUILCHER GM, Moorjani R, Truong TH, Lewis VA, et al
    Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
    Bone Marrow Transplant. 2015;50:455-6.
    PubMed     Text format    


    November 2014
  148. HENGEVELD M, Suciu S, Chelgoum Y, Marie JP, et al
    High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
    Bone Marrow Transplant. 2014 Nov 17. doi: 10.1038/bmt.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: